{
    "nct_id": "NCT05382299",
    "age": "Adults",
    "cancer_center_accrual_goal_upper": 0,
    "curated_on": "2022-05-19",
    "study_start_date": "2022-07-20",
    "study_completion_date": "",
    "data_table4": "Interventional",
    "drug_list": {
        "drug": [
            {
                "drug_name": "Drug: Gemcitabine"
            },
            {
                "drug_name": "Drug: nab-Paclitaxel"
            },
            {
                "drug_name": "Drug: Sacituzumab Govitecan-hziy"
            },
            {
                "drug_name": "Drug: Carboplatin"
            },
            {
                "drug_name": "Drug: Paclitaxel"
            }
        ]
    },
    "long_title": "A Randomized, Open-label, Phase 3 Study of Sacituzumab Govitecan Versus Treatment of Physician's Choice in Patients With Previously Untreated, Locally Advanced, Inoperable or Metastatic Triple-Negative Breast Cancer Whose Tumors Do Not Express PD-L1 or in Patients Previously Treated With Anti-PD-(L)1 Agents in the Early Setting Whose Tumors Do Express PD-L1",
    "last_updated": "2025-09-05",
    "management_group_list": {
        "management_group": [
            {
                "is_primary": "Y",
                "management_group_name": "Group1"
            }
        ]
    },
    "oncology_group_list": {
        "oncology_group": [
            {
                "group_name": "Group1",
                "is_primary": "N"
            }
        ]
    },
    "phase": "PHASE3",
    "principal_investigator": "NA, Wendy CHAN",
    "principal_investigator_institution": "Gilead Sciences, HKU",
    "program_area_list": {
        "program_area": [
            {
                "is_primary": "Y",
                "program_area_name": "Program1"
            }
        ]
    },
    "protocol_id": 0,
    "protocol_ids": [
        "GS-US-592-6238",
        "UW 23-187"
    ],
    "protocol_no": "",
    "protocol_target_accrual": 623,
    "protocol_type": "INTERVENTIONAL",
    "prior_treatment_requirements": [
        "Key Inclusion Criteria:",
        "* Individuals, regardless of race and ethnic group, with previously untreated locally advanced, inoperable or metastatic triple-negative breast cancer (TNBC)",
        "* Individuals whose tumors are programmed cell death ligand 1 (PD-L1) negative at screening or individuals whose tumors are PD-L1 positive at screening if they have received an anti-PD-(L)1 inhibitor in the (neo) adjuvant setting or if they cannot be treated with a checkpoint inhibitor due to a comorbidity",
        "* Centrally confirmed TNBC and PD-L1 status on fresh or archival tissue",
        "* Individuals must have completed treatment for Stage I-III breast cancer, if indicated, and \u2265 6 months must have elapsed (with the exception of endocrine therapy) between completion of treatment with curative intent and first documented local or distant disease recurrence",
        "* Individuals presenting with de novo metastatic TNBC are eligible",
        "* Measurable disease based on computed tomography (CT) or magnetic resonance imaging (MRI) in accordance with per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1. as evaluated locally",
        "* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1",
        "* Demonstrates adequate organ function",
        "* Male individuals and female individuals of childbearing potential who engage in heterosexual intercourse must agree to use protocol-specified method(s) of contraception",
        "* Individuals with human immunodeficiency virus (HIV) must be on antiretroviral therapy (ART) and have a well-controlled HIV infection/disease",
        "Exclude - Key Exclusion Criteria:",
        "Exclude - * Positive serum pregnancy test or women who are lactating",
        "Exclude - * Received systemic anticancer treatment within the previous 6 months or radiation therapy within 2 weeks prior to enrollment",
        "Exclude - * Have not recovered from adverse events (AEs) due to a previously administered agent at the time study entry",
        "Exclude - * May not be participating in a study with an investigational agent or investigational device within 4 weeks prior to randomization. Individuals participating in observational studies are eligible",
        "Exclude - * Previously received topoisomerase 1 inhibitors or antibody drug conjugates containing a topoisomerase inhibitor",
        "Exclude - * Active second malignancy",
        "Exclude - * Active serious infection requiring antibiotics",
        "Exclude - * Positive for HIV-1 or 2 with a history of Kaposi sarcoma and/or Multicentric Castleman Disease",
        "Exclude - * Active hepatitis B virus (HBV) or hepatitis C virus (HCV) infection",
        "Exclude - Note: Other protocol defined Inclusion/Exclusion criteria may apply."
    ],
    "short_title": "Study of Sacituzumab Govitecan-hziy Versus Treatment of Physician's Choice in Patients With Previously Untreated Locally Advanced Inoperable or Metastatic Triple-Negative Breast Cancer",
    "site_list": {
        "site": []
    },
    "sponsor_list": {
        "sponsor": [
            {
                "is_principal_sponsor": "Y",
                "sponsor_name": "Gilead Sciences",
                "sponsor_protocol_no": "",
                "sponsor_roles": "sponsor"
            }
        ]
    },
    "staff_list": {
        "protocol_staff": []
    },
    "status": "open to accrual",
    "summary": "The primary objective of this study is to compare the progression-free survival (PFS) between sacituzumab govitecan-hziy (SG) versus treatment of physician's choice (TPC) in participants with previously untreated, locally advanced, inoperable or metastatic triple-negative breast cancer whose tumors do not express programmed cell death ligand 1 (PD-L1) or in participants previously treated with anti-programmed cell death (ligand or protein) 1 (Anti-PD-(L)1) Agents in the early setting whose tumors do express PD-L1.",
    "treatment_list": {
        "step": [
            {
                "step_internal_id": 111,
                "step_code": "1",
                "step_type": "Registration",
                "arm": [
                    {
                        "arm_code": "Sacituzumab Govitecan-hziy (SG)",
                        "arm_internal_id": 0,
                        "arm_description": "Participants will receive SG 10 mg/kg on Days 1 and 8 of a 21-day cycle.",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Sacituzumab Govitecan-hziy",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            }
                        ]
                    },
                    {
                        "arm_code": "Treatment of Physician's Choice (TPC)",
                        "arm_internal_id": 1,
                        "arm_description": "Participants will receive TPC determined prior to randomization from 1 of the 3 allowed regimens:\n\n* Paclitaxel 90 mg/m\\^2 on Days 1, 8, and 15 of a 28-day cycle\n* Nab-paclitaxel 100 mg/m\\^2 on Days 1, 8, and 15 of a 28-day cycle\n* Gemcitabine 1000 mg/m\\^2 + carboplatin area under the curve (AUC) 2 on Days 1 and 8 of a 21-day cycle",
                        "arm_suspended": "N",
                        "dose_level": [
                            {
                                "level_code": "0",
                                "level_description": "Drug: Paclitaxel",
                                "level_internal_id": 0,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "1",
                                "level_description": "Drug: nab-Paclitaxel",
                                "level_internal_id": 1,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "2",
                                "level_description": "Drug: Gemcitabine",
                                "level_internal_id": 2,
                                "level_suspended": "N"
                            },
                            {
                                "level_code": "3",
                                "level_description": "Drug: Carboplatin",
                                "level_internal_id": 3,
                                "level_suspended": "N"
                            }
                        ]
                    }
                ],
                "match": [
                    {
                        "clinical": {
                            "age_numerical": ">=18",
                            "her2_status": "Negative",
                            "er_status": "Negative",
                            "pr_status": "Negative",
                            "disease_status": [
                                "Untreated",
                                "Locally Advanced",
                                "Metastatic",
                                "Recurrent",
                                "Unresectable"
                            ],
                            "oncotree_primary_diagnosis": "Invasive Breast Carcinoma"
                        }
                    }
                ]
            }
        ]
    }
}